首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1202388篇
  免费   92820篇
  国内免费   4368篇
耳鼻咽喉   17589篇
儿科学   32064篇
妇产科学   34011篇
基础医学   171024篇
口腔科学   36473篇
临床医学   102348篇
内科学   234991篇
皮肤病学   24665篇
神经病学   94562篇
特种医学   47700篇
外国民族医学   254篇
外科学   191027篇
综合类   33403篇
现状与发展   4篇
一般理论   317篇
预防医学   82827篇
眼科学   29150篇
药学   92746篇
  2篇
中国医学   3630篇
肿瘤学   70789篇
  2018年   11214篇
  2016年   9593篇
  2015年   11130篇
  2014年   16035篇
  2013年   23248篇
  2012年   31550篇
  2011年   32799篇
  2010年   19345篇
  2009年   18249篇
  2008年   30820篇
  2007年   33569篇
  2006年   33398篇
  2005年   32298篇
  2004年   31421篇
  2003年   30365篇
  2002年   29179篇
  2001年   60320篇
  2000年   61661篇
  1999年   51841篇
  1998年   13815篇
  1997年   12318篇
  1996年   11862篇
  1995年   11104篇
  1994年   10444篇
  1993年   9737篇
  1992年   41270篇
  1991年   39681篇
  1990年   38624篇
  1989年   37591篇
  1988年   34842篇
  1987年   34063篇
  1986年   32071篇
  1985年   30771篇
  1984年   22832篇
  1983年   19272篇
  1982年   11366篇
  1981年   10243篇
  1979年   21908篇
  1978年   15273篇
  1977年   12993篇
  1976年   11455篇
  1975年   12639篇
  1974年   15530篇
  1973年   14821篇
  1972年   14224篇
  1971年   13345篇
  1970年   12633篇
  1969年   12350篇
  1968年   11041篇
  1967年   10086篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
62.
63.
64.
65.
66.
67.
68.
69.
PurposeOur purpose was to determine the effect of chemoradiotherapy (CRT) on patient-reported quality of life (QOL) for patients with intact pancreas cancer.Methods and MaterialsWe reviewed a prospective QOL registry for patients with intact, clinically localized pancreatic ductal adenocarcinoma treated with CRT between June 2015 and November 2018. QOL was assessed pre-CRT (immediately before CRT, after neoadjuvant chemotherapy) and at the completion of CRT with the Functional Assessment of Cancer Therapy-Hepatobiliary (FACT-Hep) and its component parts: FACT-General (FACT-G) and hepatobiliary cancer subscore (HCS). A minimally important difference from pre-CRT was defined as ≥ 6, 5, and 8 points for FACT-G, HCS, and FACT-Hep, respectively.ResultsOf 157 patients who underwent CRT, 100 completed both pre- and post-CRT surveys and were included in the primary analysis. Median age at diagnosis was 65 years (range, 23-90). National Comprehensive Cancer Network resectability status was resectable (3%), borderline resectable (40%), or locally advanced (57%). Folinic acid, 5-fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) (75%) or gemcitabine and nab-paclitaxel (42%) were given for a median of 6 cycles (range, 0-42) before CRT. Radiation therapy techniques included 3-dimensional conformal (22%), intensity modulated photon (55%), and intensity modulated proton (23%) radiation therapy to a median dose of 50 Gy (range, 36-62.5). Concurrent chemotherapy was most commonly capecitabine (82%). Sixty-three patients (63%) had surgery after CRT. The mean decline in FACT-G, HCS subscale, and FACT-Hep from pre- to post-CRT was 3.5 (standard deviation [SD], 13.7), 1.7 (SD 7.8), and 5.2 (SD 19.4), respectively. Each of these changes were statistically significant, but did not meet the minimally important difference threshold. Pancreatic head tumor location was associated with decline in FACT-Hep. Nausea was the toxicity with the greatest increase from pre- to post-CRT by both physician-assessment and patient-reported QOL.ConclusionsFor patients with intact pancreatic adenocarcinoma, modern CRT is well tolerated with minimal decline in QOL during treatment.  相似文献   
70.
The retroviral protease of human immunodeficiency virus (HIV) is an excellent target for antiviral inhibitors for treating HIV/AIDS. Despite the efficacy of therapy, current efforts to control the disease are undermined by the growing threat posed by drug resistance. This review covers the historical background of studies on the structure and function of HIV protease, the subsequent development of antiviral inhibitors, and recent studies on drug-resistant protease variants. We highlight the important contributions of Dr. Stephen Oroszlan to fundamental knowledge about the function of the HIV protease and other retroviral proteases. These studies, along with those of his colleagues, laid the foundations for the design of clinical inhibitors of HIV protease. The drug-resistant protease variants also provide an excellent model for investigating the molecular mechanisms and evolution of resistance.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号